Daptomycin in experimental murine pneumococcal meningitis

Barry B. Mook-Kanamori, Mark S. Rouse, Cheol In Kang, Diederik van de Beek, James M. Steckelberg, Robin Patel

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Daptomycin, a lipopeptide antibiotic, could be an alternative to vancomycin for treatment of pneumococcal meningitis. We determined the activity of daptomycin versus vancomycin, with dexamethasone as an adjuvant, in a murine model of pneumococcal meningitis. Methods: Ninety-six 25-30 gram mice were inoculated intracisternally with serotype 3 Streptococcus pneumoniae modified by the integration of a luminescent lux operon. All mice were treated with either dexamethasone 1 mg/kg intraperitoneally every 6 hours alone or in combination with either vancomycin or daptomycin, also administered intraperitoneally. Serum antimicrobial concentrations were selected to approximate those achieved in humans. Following treatment, bioluminescence and cerebrospinal fluid (CSF) bacterial concentrations were determined. Caspase-3 staining was used to assess apoptosis on brain histopathology. Results: Sixteen hours post intracisternal inoculation, bacterial titers in CSF were 6.8 log10 cfu/ml. Amongst the animals given no antibiotic, vancomycin 50 mg/kg at 16 and 20 hours or daptomycin 25 mg/ kg at 16 hours, CSF titers were 7.6, 3.4, and 3.9 log10 cfu/ ml, respectively, at 24 hours post infection (p-value, < 0.001 for both vancomycin or daptomycin versus no antibiotic); there was no significant difference in bactericidal activity between the vancomycin and daptomycin groups (p-value, 0.18). CSF bioluminescence correlated with bacterial titer (Pearson regression coefficient, 0.75). The amount of apoptosis of brain parenchymal cells was equivalent among treatment groups. Conclusion: Daptomycin or vancomycin, when given in combination with dexamethasone, is active in the treatment of experimental pneumococcal meningitis.

Original languageEnglish (US)
Article number50
JournalBMC Infectious Diseases
Volume9
DOIs
StatePublished - Apr 30 2009

Fingerprint

Daptomycin
Pneumococcal Meningitis
Vancomycin
Cerebrospinal Fluid
Dexamethasone
Anti-Bacterial Agents
Apoptosis
Lipopeptides
Brain
Operon
Streptococcus pneumoniae
Caspase 3
Staining and Labeling
Infection
Serum

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Mook-Kanamori, B. B., Rouse, M. S., Kang, C. I., van de Beek, D., Steckelberg, J. M., & Patel, R. (2009). Daptomycin in experimental murine pneumococcal meningitis. BMC Infectious Diseases, 9, [50]. https://doi.org/10.1186/1471-2334-9-50

Daptomycin in experimental murine pneumococcal meningitis. / Mook-Kanamori, Barry B.; Rouse, Mark S.; Kang, Cheol In; van de Beek, Diederik; Steckelberg, James M.; Patel, Robin.

In: BMC Infectious Diseases, Vol. 9, 50, 30.04.2009.

Research output: Contribution to journalArticle

Mook-Kanamori, BB, Rouse, MS, Kang, CI, van de Beek, D, Steckelberg, JM & Patel, R 2009, 'Daptomycin in experimental murine pneumococcal meningitis', BMC Infectious Diseases, vol. 9, 50. https://doi.org/10.1186/1471-2334-9-50
Mook-Kanamori BB, Rouse MS, Kang CI, van de Beek D, Steckelberg JM, Patel R. Daptomycin in experimental murine pneumococcal meningitis. BMC Infectious Diseases. 2009 Apr 30;9. 50. https://doi.org/10.1186/1471-2334-9-50
Mook-Kanamori, Barry B. ; Rouse, Mark S. ; Kang, Cheol In ; van de Beek, Diederik ; Steckelberg, James M. ; Patel, Robin. / Daptomycin in experimental murine pneumococcal meningitis. In: BMC Infectious Diseases. 2009 ; Vol. 9.
@article{ec672199e27f4f03a26d9ecf57ec8ff7,
title = "Daptomycin in experimental murine pneumococcal meningitis",
abstract = "Background: Daptomycin, a lipopeptide antibiotic, could be an alternative to vancomycin for treatment of pneumococcal meningitis. We determined the activity of daptomycin versus vancomycin, with dexamethasone as an adjuvant, in a murine model of pneumococcal meningitis. Methods: Ninety-six 25-30 gram mice were inoculated intracisternally with serotype 3 Streptococcus pneumoniae modified by the integration of a luminescent lux operon. All mice were treated with either dexamethasone 1 mg/kg intraperitoneally every 6 hours alone or in combination with either vancomycin or daptomycin, also administered intraperitoneally. Serum antimicrobial concentrations were selected to approximate those achieved in humans. Following treatment, bioluminescence and cerebrospinal fluid (CSF) bacterial concentrations were determined. Caspase-3 staining was used to assess apoptosis on brain histopathology. Results: Sixteen hours post intracisternal inoculation, bacterial titers in CSF were 6.8 log10 cfu/ml. Amongst the animals given no antibiotic, vancomycin 50 mg/kg at 16 and 20 hours or daptomycin 25 mg/ kg at 16 hours, CSF titers were 7.6, 3.4, and 3.9 log10 cfu/ ml, respectively, at 24 hours post infection (p-value, < 0.001 for both vancomycin or daptomycin versus no antibiotic); there was no significant difference in bactericidal activity between the vancomycin and daptomycin groups (p-value, 0.18). CSF bioluminescence correlated with bacterial titer (Pearson regression coefficient, 0.75). The amount of apoptosis of brain parenchymal cells was equivalent among treatment groups. Conclusion: Daptomycin or vancomycin, when given in combination with dexamethasone, is active in the treatment of experimental pneumococcal meningitis.",
author = "Mook-Kanamori, {Barry B.} and Rouse, {Mark S.} and Kang, {Cheol In} and {van de Beek}, Diederik and Steckelberg, {James M.} and Robin Patel",
year = "2009",
month = "4",
day = "30",
doi = "10.1186/1471-2334-9-50",
language = "English (US)",
volume = "9",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Daptomycin in experimental murine pneumococcal meningitis

AU - Mook-Kanamori, Barry B.

AU - Rouse, Mark S.

AU - Kang, Cheol In

AU - van de Beek, Diederik

AU - Steckelberg, James M.

AU - Patel, Robin

PY - 2009/4/30

Y1 - 2009/4/30

N2 - Background: Daptomycin, a lipopeptide antibiotic, could be an alternative to vancomycin for treatment of pneumococcal meningitis. We determined the activity of daptomycin versus vancomycin, with dexamethasone as an adjuvant, in a murine model of pneumococcal meningitis. Methods: Ninety-six 25-30 gram mice were inoculated intracisternally with serotype 3 Streptococcus pneumoniae modified by the integration of a luminescent lux operon. All mice were treated with either dexamethasone 1 mg/kg intraperitoneally every 6 hours alone or in combination with either vancomycin or daptomycin, also administered intraperitoneally. Serum antimicrobial concentrations were selected to approximate those achieved in humans. Following treatment, bioluminescence and cerebrospinal fluid (CSF) bacterial concentrations were determined. Caspase-3 staining was used to assess apoptosis on brain histopathology. Results: Sixteen hours post intracisternal inoculation, bacterial titers in CSF were 6.8 log10 cfu/ml. Amongst the animals given no antibiotic, vancomycin 50 mg/kg at 16 and 20 hours or daptomycin 25 mg/ kg at 16 hours, CSF titers were 7.6, 3.4, and 3.9 log10 cfu/ ml, respectively, at 24 hours post infection (p-value, < 0.001 for both vancomycin or daptomycin versus no antibiotic); there was no significant difference in bactericidal activity between the vancomycin and daptomycin groups (p-value, 0.18). CSF bioluminescence correlated with bacterial titer (Pearson regression coefficient, 0.75). The amount of apoptosis of brain parenchymal cells was equivalent among treatment groups. Conclusion: Daptomycin or vancomycin, when given in combination with dexamethasone, is active in the treatment of experimental pneumococcal meningitis.

AB - Background: Daptomycin, a lipopeptide antibiotic, could be an alternative to vancomycin for treatment of pneumococcal meningitis. We determined the activity of daptomycin versus vancomycin, with dexamethasone as an adjuvant, in a murine model of pneumococcal meningitis. Methods: Ninety-six 25-30 gram mice were inoculated intracisternally with serotype 3 Streptococcus pneumoniae modified by the integration of a luminescent lux operon. All mice were treated with either dexamethasone 1 mg/kg intraperitoneally every 6 hours alone or in combination with either vancomycin or daptomycin, also administered intraperitoneally. Serum antimicrobial concentrations were selected to approximate those achieved in humans. Following treatment, bioluminescence and cerebrospinal fluid (CSF) bacterial concentrations were determined. Caspase-3 staining was used to assess apoptosis on brain histopathology. Results: Sixteen hours post intracisternal inoculation, bacterial titers in CSF were 6.8 log10 cfu/ml. Amongst the animals given no antibiotic, vancomycin 50 mg/kg at 16 and 20 hours or daptomycin 25 mg/ kg at 16 hours, CSF titers were 7.6, 3.4, and 3.9 log10 cfu/ ml, respectively, at 24 hours post infection (p-value, < 0.001 for both vancomycin or daptomycin versus no antibiotic); there was no significant difference in bactericidal activity between the vancomycin and daptomycin groups (p-value, 0.18). CSF bioluminescence correlated with bacterial titer (Pearson regression coefficient, 0.75). The amount of apoptosis of brain parenchymal cells was equivalent among treatment groups. Conclusion: Daptomycin or vancomycin, when given in combination with dexamethasone, is active in the treatment of experimental pneumococcal meningitis.

UR - http://www.scopus.com/inward/record.url?scp=66749117734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66749117734&partnerID=8YFLogxK

U2 - 10.1186/1471-2334-9-50

DO - 10.1186/1471-2334-9-50

M3 - Article

C2 - 19405978

AN - SCOPUS:66749117734

VL - 9

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

M1 - 50

ER -